Johnson & Johnson’s talc multidistrict litigation reached a new milestone on January 21, 2026 when U.S. District Court Special Master L. Wolfson issued an opinion that allows plaintiffs to present expert testimony supporting general causation for ovarian cancer linked to the perineal use of talc. The ruling removes a procedural barrier that had previously limited the evidence plaintiffs could introduce, thereby broadening the evidentiary scope for the more than 67,500 lawsuits that have been filed against the company.
The Special Master’s decision is a significant regulatory action because it permits expert witnesses to argue that talc use can cause ovarian cancer, a claim that has been central to the plaintiffs’ cases. By opening the door to general causation evidence, the ruling could increase the likelihood of adverse verdicts and raise Johnson & Johnson’s legal exposure. The company’s legal chief, Erik Haas, said the firm will appeal the decision, indicating that the company views the ruling as a material threat to its litigation strategy and reserve calculations.
On the same day, Johnson & Johnson reported its fourth‑quarter 2025 earnings. Revenue rose 9.1% to $24.56 billion, beating the consensus estimate of $24.40 billion. Adjusted earnings per share matched the consensus of $2.46, slightly beating the Zacks estimate of $2.43. The revenue growth was driven by a 10% increase in Innovative Medicine sales, led by oncology drugs such as Darzalex, Carvykti, and Erleada, and a 7.5% rise in MedTech sales, powered by cardiovascular and surgical products.
Management guided for 2026 with mid‑point estimates of $100.5 billion in reported sales and $11.53 in adjusted EPS. The guidance is only marginally above consensus, which has tempered investor enthusiasm. Analysts noted that the modest upside in revenue guidance, coupled with expectations of higher costs, has led to a muted market reaction.
The combination of the Special Master’s ruling and the earnings beat underscores the dual pressures Johnson & Johnson faces: a growing litigation risk that could inflate reserve requirements and a business that continues to grow through innovation but must navigate cost pressures and a cautious outlook. The company’s strategy to appeal the decision and its focus on high‑margin oncology and MedTech segments signal a commitment to maintaining profitability while managing legal exposure.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.